ATXS Stock Price, Astria Therapeutics, . Quote, Chart

Market Summary

USD9.01-0.63

Market Closed

-6.54%

ATXS Alerts

1 major insider sales recently.

ATXS Stock Price

View Fullscreen

ATXS RSI Chart

ATXS Valuation

Market Cap

529.3M

Price/Earnings (Trailing)

-7.26

Price/Free Cashflow

-7.73

ATXS Price/Earnings (Trailing)

ATXS Profitability

Return on Equity

-29.98%

Return on Assets

-28.62%

Free Cashflow Yield

-12.94%

ATXS Fundamentals

ATXS Earnings

Earnings (TTM)

-72.9M

Earnings Growth (Yr)

-136.82%

Earnings Growth (Qtr)

-77.19%

Breaking Down ATXS Revenue

Last 7 days

-13.1%

Last 30 days

-36.3%

Last 90 days

13.4%

Trailing 12 Months

-21.4%

How does ATXS drawdown profile look like?

ATXS Financial Health

Current Ratio

21.73

ATXS Investor Care

Shares Dilution (1Y)

115.72%

Diluted EPS (TTM)

-2.42

Tracking the Latest Insider Buys and Sells of Astria Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	morabito christopher	sold	-135,939	13.5939	-10,000	chief medical officer
Apr 01, 2024	morabito christopher	acquired	38,700	3.87	10,000	chief medical officer
Feb 01, 2024	perceptive advisors llc	bought	29,999,500	12.09	2,481,350	-
Jan 29, 2024	morabito christopher	sold	-102,552	11.147	-9,200	chief medical officer
Jan 29, 2024	morabito christopher	acquired	35,604	3.87	9,200	chief medical officer
Jan 26, 2024	morabito christopher	sold	-8,812	11.015	-800	chief medical officer
Jan 26, 2024	morabito christopher	acquired	3,096	3.87	800	chief medical officer
Dec 21, 2023	perceptive advisors llc	bought	4,588,000	6.2	740,000	-
Oct 16, 2023	perceptive advisors llc	bought	7,000,000	6.514	1,074,610	-
Dec 19, 2022	perceptive advisors llc	bought	10,000,000	11.01	908,265	-

Which funds bought or sold ATXS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	AMALGAMATED BANK	reduced	-51.2	-2,000	24,000	-%
Apr 22, 2024	Vivo Capital, LLC	reduced	-6.19	13,713,700	32,781,100	2.58%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	2,986	104,241	-%
Apr 19, 2024	Red Tortoise LLC	unchanged	-	1,905	4,194	-%
Apr 11, 2024	Fortitude Family Office, LLC	unchanged	-	25.00	56.00	-%
Apr 05, 2024	CWM, LLC	unchanged	-	1,000	1,000	-%
Apr 05, 2024	GAMMA Investing LLC	added	5.79	803	6,432	-%
Mar 11, 2024	VANGUARD GROUP INC	added	36.15	4,523,820	15,787,800	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	14.8	38,703	251,536	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	added	28.97	31,174	126,282	-%

Are Funds Buying or Selling ATXS?

Are funds buying ATXS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ATXS

No. of Funds

ATXS Alerts

1 major insider sales recently.

Unveiling Astria Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 11, 2024	fmr llc	-	0	SC 13G/A
Mar 07, 2024	blackrock inc.	4.5%	2,455,653	SC 13G/A
Feb 14, 2024	deep track capital, lp	0%	0	SC 13G/A
Feb 14, 2024	fairmount funds management llc	9.9%	3,633,965	SC 13G/A
Feb 14, 2024	cormorant asset management, lp	0.00%	0	SC 13G/A
Feb 13, 2024	vivo opportunity, llc	4.5%	2,482,727	SC 13G/A
Feb 13, 2024	vanguard group inc	5.66%	2,055,707	SC 13G
Feb 12, 2024	ra capital management, l.p.	8.1%	4,413,150	SC 13G
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 05, 2024	perceptive advisors llc	11.9%	6,485,420	SC 13D/A

Recent SEC filings of Astria Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	ARS	ARS
Apr 22, 2024	DEF 14A	DEF 14A
Apr 22, 2024	DEFA14A	DEFA14A
Apr 09, 2024	3	Insider Trading
Apr 09, 2024	4	Insider Trading
Apr 09, 2024	8-K	Current Report
Apr 03, 2024	4	Insider Trading
Apr 01, 2024	144	Notice of Insider Sale Intent
Mar 25, 2024	8-K	Current Report
Mar 11, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Astria Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	2.33%	-21.90%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-0.30%	-28.67%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	8.14%	-4.26%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-6.36%	-10.84%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-10.64%	-48.02%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	8.01%	271.09%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-10.76%	0.48%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	76.15%	62.71%	-0.24	2.14	-13.45%	66.37%

Astria Therapeutics, Inc. News

Latest updates

Astria Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	31.4%	255	194	207	218	231	120	105	115	128	135	141	149	47.00	57.00	57.00	59.00	42.00	44.00	49.00	54.00	39.00
Current Assets	31.1%	251	191	204	215	228	118	104	114	127	135	140	148	46.00	56.00	56.00	57.00	39.00	43.00	47.00	53.00	39.00
Cash Equivalents	46.5%	176	120	134	202	21.00	46.00	30.00	47.00	87.00	132	140	147	25.00	53.00	52.00	13.00	10.00	18.00	10.00	12.00	15.00
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00
Liabilities	23.1%	12.00	9.00	7.00	7.00	9.00	7.00	6.00	5.00	5.00	5.00	4.00	9.00	7.00	8.00	6.00	5.00	6.00	6.00	5.00	5.00	4.00
Current Liabilities	23.1%	12.00	9.00	7.00	7.00	9.00	6.00	5.00	5.00	5.00	5.00	4.00	4.00	6.00	7.00	6.00	5.00	5.00	6.00	5.00	4.00	4.00
Shareholder's Equity	31.8%	243	184	200	211	221	113	99.00	110	122	130	137	330	41.00	49.00	0.00	54.00	36.00	38.00	254	253	35.00
Retained Earnings	-5.7%	-580	-549	-531	-518	-507	-494	-482	-471	-455	-446	-438	-431	-260	-251	-241	-231	-223	-216	-210	-203	-197
Additional Paid-In Capital	14.1%	728	638	636	635	633	511	486	484	482	480	475	330	302	301	292	285	259	255	254	253	232
Shares Outstanding	46.3%	41.00	28.00	28.00	28.00	28.00	14.00	13.00	13.00	13.00	8.00	5.00	4.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	280	-	-	-	26.00	-	-	-	130	-	-	-	101	-	-	-	73.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-112.1%	-30,238	-14,258	-10,696	-13,253	-10,664	-10,249	-10,061	-12,559	-6,286	-7,749	-7,400	-8,716	-8,061	-9,969	-7,466	-6,989	-7,770	-6,474	-5,738	-6,587	-5,269
Share Based Compensation	22.1%	2,069	1,694	1,331	1,220	1,073	1,155	1,117	1,209	972	1,010	1,014	366	305	375	-	-	285	378	441	408	431
Cashflow From Investing	-50300.0%	-2,016	-4.00	-57,920	194,992	-135,180	1,950	-6,800	-27,099	-39,000	-	-	26,445	-20,010	2,000	39,742	-15,432	-3,504	13,651	3,509	-17,738	1,094
Cashflow From Financing	79880.0%	87,978	110	273	37.00	120,397	-	-	-	17.00	6.00	-	104,261	31.00	8,940	6,265	25,624	3,772	973	192	20,683	-407

ATXS Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 42,127	$ 34,264
General and administrative	25,704	19,239
Acquired in-process research and development	15,199
Total operating expenses	83,030	53,503
Loss from operations	(83,030)	(53,503)
Other income (expense):
Interest and investment income	10,201	1,724
Other expense, net	(62)	(55)
Total other income, net	10,139	1,669
Net loss	$ (72,891)	$ (51,834)
Net loss per share attributable to common shareholders - basic	$ (2.42)	$ (3.55)
Net loss per share attributable to common shareholders - diluted	$ (2.42)	$ (3.55)
Weighted-average common shares outstanding used in net loss per share - basic	30,123,316	14,620,618
Weighted-average common shares outstanding used in net loss per share - diluted	30,123,316	14,620,618

ATXS Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 175,530	$ 20,525
Short-term investments	71,000	205,912
Prepaid expenses and other current assets	4,412	1,253
Total current assets	250,942	227,690
Right-of-use asset	363	948
Other assets	3,361	1,995
Total assets	254,666	230,633
Current liabilities:
Accounts payable	1,513	788
Accrued expenses	9,708	7,690
Current portion of operating lease liabilities	329	582
Total current liabilities	11,550	9,060
Long term portion of operating lease liabilities		357
Total liabilities	11,550	9,417
Commitments (Note 6)
Stockholders' equity:
Common stock, $0.001 par value per share, 150,000,000 shares authorized; 41,034,797 and 27,501,340 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	41	28
Additional paid-in capital	728,285	632,512
Accumulated other comprehensive loss		(79)
Accumulated deficit	(580,534)	(507,643)
Total stockholders' equity	243,116	221,216
Total liabilities and stockholders' equity	254,666	230,633
Preferred stock
Stockholders' equity:
Preferred stock
Series X redeemable convertible preferred stock
Stockholders' equity:
Preferred stock	$ 95,324	$ 96,398

About Astria Therapeutics, Inc.

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in clinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.

CEO	Ms. Jill C. Milne Ph.D.
WEBSITE	astriatx.com
INDUSTRY	Biotechnology
EMPLOYEES	45

Astria Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Astria Therapeutics, Inc.? What does ATXS stand for in stocks?

ATXS is the stock ticker symbol of Astria Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Astria Therapeutics, Inc. (ATXS)?

As of Tue Apr 23 2024, market cap of Astria Therapeutics, Inc. is 529.27 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ATXS stock?

You can check ATXS's fair value in chart for subscribers.

What is the fair value of ATXS stock?

You can check ATXS's fair value in chart for subscribers. The fair value of Astria Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Astria Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ATXS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Astria Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether ATXS is over valued or under valued. Whether Astria Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Astria Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ATXS.